Aromatase Inhibitor News and Research

RSS

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.

New treatment approach improves recurrence-free survival in early breast cancer patients

A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.

20 Mar 2024

The metabolic effects of endocrine therapy on diabetes mellitus in breast cancer survivors

Researchers discuss the history of endocrine therapies, highlights their adverse metabolic effects, and emphasizes the need for better biomarkers of diabetes.

5 Oct 2023

Less is more: Radiotherapy omission deemed safe for certain breast cancer patients

The risk of breast cancer recurrence after breast-conserving surgery.

22 Aug 2023

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology's annual meeting.

23 May 2023

Cyclical estrogen/anti-estrogen therapy could be a promising strategy to treat metastatic ER+ breast cancer

Advanced or metastatic estrogen receptor-positive (ER+) breast cancer is commonly treated with drugs that block the estrogen receptor.

15 May 2023

Addition of capivasertib to fulvestrant doubles progression-free survival in HR-positive breast cancer patients

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Study reports overall response of HER2-low breast cancer patients to neoadjuvant T-DXd treatment

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Combination therapy shows promising results in patients with recurrent ER-positive endometrial cancer

A combination therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in 75% of patients with recurrent or persistent estrogen receptor- (ER-) positive endometrial cancer, results from a recent clinical trial show.

19 Mar 2022

Ribociclib plus endocrine therapy offers survival benefit for postmenopausal patients with metastatic breast cancer

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

10 Mar 2022

KU researcher wins $1.25 million award to investigate the vital role of sex hormones in tissue repair

Our ability to heal and regenerate new tissue after an injury has much to do with biological sex. For instance, following menopause, the loss of sex-hormone signaling in women can lead to degenerative diseases such as osteoporosis and osteoarthritis, where bone and cartilage degrade and become more delicate and brittle because of tissue loss.

21 Sep 2021

Novel anti-hormonal therapy may be a new treatment option for early-stage breast cancer

Early results from a UCLA-led clinical trial found treating women with estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER2)-negative early breast cancers with a novel type of anti-hormonal therapy, called an oral selective estrogen receptor degrader (SERD), led to clinically meaningful reductions in tumor activity prior to surgery.

21 Sep 2021

Blood serum test can identify which breast cancer patients have slow-growing disease

Researchers with the SWOG Cancer Research Network have found that patients with metastatic hormone receptor-positive breast cancer who have low activity levels of the enzyme sTK1 in their blood serum at the start of anti-estrogen treatment live longer and go longer without their disease progressing than patients with high levels.

14 Sep 2021

Molecular imaging can predict response to novel metastatic breast cancer treatment

Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy.

17 Feb 2021

Study shows association between chemotherapy benefit and menopausal status in breast cancer patients

After a median follow-up of 5.1 years, among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, postmenopausal patients had no added benefit from chemotherapy, while premenopausal patients who received chemotherapy had improved invasive disease-free survival (IDFS) and an early indication of improved overall survival (OS), according to data from the SWOG S1007 RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Study uncovers the locus of male sexual desire in the brain

The locus of male sexual desire has been uncovered in specific regions of brain tissue where a key gene named aromatase is present, reports a new Northwestern Medicine study in mice.

12 Sep 2020

Women with T1a breast cancers could benefit from hormone treatment

Many people diagnosed with breast cancers that are small but invasive could benefit from hormone treatment, a new study led by physicians at Roswell Park Comprehensive Cancer Center confirms. Their findings were published today in the journal JAMA Network Open.

24 Aug 2020

Surgical delay does not lower overall survival of women with early-stage breast cancer

A new breast cancer study brings reassuring findings for women with early-stage breast cancer who were forced to delay their cancer operations because of the Coronavirus Disease 2019 (COVID-19) pandemic.

6 Aug 2020

Newer data confirms survival advantages, but also side effects for ribociclib in breast cancer

In 2017 and 2019, the German Institute for Quality and Efficiency in Health Care had already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor or fulvestrant in comparison with the appropriate comparator therapy in patients after menopause, with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer.

5 Jun 2020

Study provides new insight into neurofibromin-deficient ER+ breast cancer

An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.

5 Mar 2020

Patient-reported outcomes linked to aromatase inhibitor adherence

If you want to predict which breast cancer patients will most likely stop taking aromatase inhibitors, check out their own responses to the health questions patients commonly answer in cancer clinical trials, according to research findings to be presented Friday, Dec. 13 at the San Antonio Breast Cancer Symposium.

13 Dec 2019